title: [Comparison of the effects of phosphodiesterase III inhibitors, milrinone and olprinone, in infant corrective cardiac surgery].
abstract: BACKGROUND
  Clinical characteristics of phosphodiesterase (PDE) III inhibitors, milrinone and olprinone, is not fully understood in infants. We therefore retrospectively examined the hemodynamics, metabolism, and oxygenation of two different PDE III inhibitors in infants undergoing radical correction of ventricular septal defect with pulmonary hypertension.
  
  
  METHODS
  Twenty-six infants with pulmonary hypertension undergoing ventricular septum defect repair were retrospectively allocated to milrinone group (n= 13)and olprinone group(n=13). Hemodynamic parameters, acid-base balance, oxygenation and postoperative mechanical ventilation period were compared between the two groups at induction of anesthesia, weaning from cardiopulmonary bypass and the end of the surgery.
  
  
  RESULTS
  The patients' mean age was 4.4 +/- 2.5 months. Demographic data were almost similar between the two groups. Milrinone and olprinone were administered at the rates of 0.5 and 0.3 microg x kg-1 x min-1 at the end of surgery, respectively. Hemodynamic variables, acid-base balance, Pao2 /FIo2 ratio and mechanical ventilation period were not significantly different between the two groups. No adverse side effects were observed during the study period.
  
  
  CONCLUSIONS
  The effects of the PDE III inhibitors, milrinone and olprinone, on hemodynamic parameters, acid-base balance and oxygenation were similar in these infants. Both milrinone and olprinone could be used safely in infant cardiac surgery.
authors.affiliation: Department ofAnesthesia, Fukuoka Children's Hospital and Medical Center for Infectious Diseases, Fukuoka 810-0063.
authors.forename: Shotaro
authors.initials: S
authors.lastname: Sakimura
authors.forename: Jun
authors.initials: J
authors.lastname: Yoshino
authors.forename: Kaoru
authors.initials: K
authors.lastname: Izumi
authors.forename: Nobuo
authors.initials: N
authors.lastname: Jimi
authors.forename: Rieko
authors.initials: R
authors.lastname: Sumiyoshi
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Mizuno
mesh_terms: D006348:Cardiac Surgical Procedures; D005260:Female; D006345:Heart Septal Defects, Ventricular / Q000150:complications* / Q000503:physiopathology / Q000601:surgery*; D006439:Hemodynamics; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D007093:Imidazoles / Q000008:administration & dosage*; D007223:Infant; D007430:Intraoperative Care; D008297:Male; D020105:Milrinone / Q000008:administration & dosage*; D058987:Phosphodiesterase 3 Inhibitors / Q000008:administration & dosage*; D011728:Pyridones / Q000008:administration & dosage*; D012189:Retrospective Studies
chemical_list: D007093:Imidazoles; D058987:Phosphodiesterase 3 Inhibitors; D011728:Pyridones; C059498:olprinone; D020105:Milrinone